Compositions and methods for inhibiting expression of Factor V Leiden mutant gene

Details for Australian Patent Application No. 2011200894 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Vornlocher, Hans-Peter; Maraganore, John M.

Agent FB Rice

Pub. Number AU-A-2011200894

Parent 2006311730

Filing date 1 March 2011

Wipo publication date 24 March 2011

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

17 March 2011 Complete Application Filed

24 March 2011 Application Open to Public Inspection

  Published as AU-A-2011200894

19 July 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(c). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011200895-Knotless endostitch package

2011200893-Device for hardening rails